Pulmonary hypertension (PH) is a complex and progressive condition characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance, leading to right heart failure if untreated. This article aims to provide an in-depth exploration of the condition's fundamental aspects.
PH is categorized into five groups based on its etiology, including pulmonary arterial hypertension, PH due to left heart disease, PH due to lung diseases and/or hypoxia, chronic thromboembolic PH, and PH with unclear and/or multifactorial mechanisms. Regardless of the cause, the pathophysiology of PH involves three key processes: vasoconstriction, vascular remodeling, and thrombosis.
PH often presents with nonspecific symptoms such as dyspnea, fatigue, and syncope, making early diagnosis challenging. Diagnostic evaluation typically involves echocardiography, right heart catheterization, and various other imaging and laboratory tests to identify the underlying cause.
Management of PH is multidimensional, involving lifestyle modifications, pharmacologic therapies, and in severe cases, surgical interventions. Pharmacologic treatment options include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs, among others. Lung transplantation may be considered in patients with advanced disease.
The prognosis of PH is generally poor due to its progressive nature. However, early diagnosis and appropriate management can significantly improve patients' quality of life and survival rates.
PH is a complex disease with a multifactorial etiology and pathophysiology. Despite the challenges in early diagnosis and management, a thorough understanding of its fundamental aspects can guide clinicians in providing optimal care for patients with this condition. Continued research and advances in treatment options promise to improve the prognosis of this debilitating disease.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation